Tucatinib,Trastuzumab,fulvestrant
Seagen
['bcsm', 'trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'tucatinib']
tucatinib and trastuzumab in her2+ biliary tract cancer: 46.7% orr, 1 cr median dor: 6 months median pfs and os: 5.5 and 15.5 months, respectively. chemo-free regimen
very encouraging! #asco23 #hpbcsm #cancerresearch 
GI #Oncologist @ClevelandClinic | @USNews contributor | Tweets my own